SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000891293-21-000030
Filing Date
2021-06-07
Accepted
2021-06-07 17:28:01
Documents
14
Period of Report
2021-06-02
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K ctic-20210602.htm   iXBRL 8-K 61310
2 EX-10.1 ex101amendedandrestated201.htm EX-10.1 111879
3 EX-10.2 ex102amendedandrestated200.htm EX-10.2 74640
  Complete submission text file 0000891293-21-000030.txt   427199

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ctic-20210602.xsd EX-101.SCH 1939
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ctic-20210602_lab.xml EX-101.LAB 24335
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ctic-20210602_pre.xml EX-101.PRE 12681
7 EXTRACTED XBRL INSTANCE DOCUMENT ctic-20210602_htm.xml XML 10531
Mailing Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121
Business Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121 2062827100
CTI BIOPHARMA CORP (Filer) CIK: 0000891293 (see all company filings)

IRS No.: 911533912 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-28386 | Film No.: 211000494
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences